Wilserdly (giredestrant): FDA approval, pivotal trial and safety

Approved
Type
New molecular entity · Oral
FDA-approved use
To treat adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, estrogen receptor 1-mutated locally advanced or metastatic breast cancer whose disease has recurred during or after endocrine-based adjuvant therapy, or has progressed on at least one endocrine-based regimen in the metastatic settingWording from FDA's list of novel approvals.
FDA review
Standard review
Company
Genentech
Application
NDA 220791
Specialty
Oncology

At a glance

Wilserdly (giredestrant) is an oral selective estrogen receptor antagonist and degrader. It is approved for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer that has recurred after endocrine-based adjuvant therapy or progressed on at least one endocrine-based regimen for metastatic disease. In the phase 3 evERA trial, giredestrant plus everolimus cut the risk of progression or death in ESR1-mutated disease (hazard ratio 0.38; median 10.0 vs 5.5 months). Adverse events were similar to the comparator arm, led by stomatitis, diarrhea, and anemia.

What it is and how it works

Giredestrant binds the estrogen receptor, blocks it, and promotes its degradation. It is taken by mouth. Fulvestrant also degrades the receptor but is given by injection. Aromatase inhibitors lower estrogen levels instead of acting on the receptor, and tamoxifen is a receptor modulator rather than a degrader. Because it acts on the receptor itself, giredestrant may keep working in tumors with ESR1 mutations, which can drive resistance to aromatase inhibitors.

Pivotal trials

evERA Breast Cancer NCT05306340

Design
Phase 3, open-label, randomized 1:1 trial of an all-oral regimen.
Patients
373 patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer that progressed or recurred after a CDK4/6 inhibitor plus endocrine therapy; 207 had ESR1-mutated tumors.
Compared with
Standard endocrine therapy (exemestane, fulvestrant, or tamoxifen) plus everolimus.
Primary endpoint
Investigator-assessed progression-free survival, tested first in the ESR1-mutated group and then in the overall population.

Result

In ESR1-mutated tumors, median progression-free survival was 10.0 vs 5.5 months (hazard ratio 0.38; 95% CI 0.27 to 0.54; P<0.001). In the overall population it was 8.8 vs 5.5 months (hazard ratio 0.56; 95% CI 0.44 to 0.71; P<0.001).

Other results
Not reported in the sources.
Safety in the trial
Adverse events occurred in 98.9% with giredestrant-everolimus and 96.8% with the comparator. Stomatitis occurred in 47.3% vs 48.9%, diarrhea in 26.9% vs 22.6%, and anemia in 23.6% vs 21.0%.

Source: Mayer EL, et al. Giredestrant plus Everolimus in Advanced Breast Cancer. N Engl J Med. 2026;395:1285-1298.

EvidencePulse™

Ask about Wilserdly

The question that opens in EvidencePulse

How does Wilserdly (giredestrant) compare with the alternatives (Fulvestrant, Aromatase inhibitors (exemestane), Everolimus with endocrine therapy) for adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, estrogen receptor 1-mutated locally advanced or metastatic breast cancer whose disease has recurred during or after endocrine-ba…? Summarize head-to-head and indirect evidence, efficacy, safety and where each fits, with citations.

Ask in EvidencePulseFree to try, more with 2MM+.

Deep research is a core feature of 2MM Max.

Safety signals

There is no boxed warning. In the evERA trial, nearly all patients had an adverse event, and rates were close to those with standard endocrine therapy plus everolimus. The most common events were stomatitis, diarrhea, and anemia, and much of this profile likely reflects everolimus. In the phase 2 coopERA study of giredestrant plus palbociclib, neutropenia was the leading grade 3-4 event and serious adverse events were uncommon. One patient in that study died of myocardial infarction. Check the full label for warnings and precautions.

What it competes with

Treatment after progression on endocrine therapy and a CDK4/6 inhibitor depends on biomarkers and prior therapy. Options include endocrine monotherapy, endocrine therapy combined with targeted agents, and later chemotherapy.

  • FulvestrantInjectable estrogen receptor degrader, used alone or with targeted agents.
  • Aromatase inhibitors (exemestane)Lower estrogen production; activity may be limited in ESR1-mutated disease.
  • Everolimus with endocrine therapymTOR inhibitor combination used after CDK4/6 inhibitor progression; stomatitis is common.
  • TamoxifenOral estrogen receptor modulator, sometimes used in later lines.
  • ChemotherapyUsed when endocrine options are exhausted or rapid disease control is needed.

Bottom line for clinicians

Wilserdly is for adults with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer after prior endocrine-based therapy. The pivotal trial was open label and used investigator-assessed progression-free survival, and the benefit was concentrated in ESR1-mutated tumors. Weigh the everolimus-related toxicity of the studied combination, and confirm ESR1 status before use.

Our coverage

Sources

  1. Full prescribing information (FDA)
  2. FDA list of novel approvals
  3. Mayer EL, et al. Giredestrant plus Everolimus in Advanced Breast Cancer. N Engl J Med. 2026;395:1285-1298.
  4. ClinicalTrials.gov NCT05306340
  5. Kuemmel S, et al. heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer. BMC Cancer. 2024;24:641.
  6. Hurvitz SA, et al. Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study. Lancet Oncol. 2023;24:1029-1041.

Dosing, contraindications and full warnings are in the prescribing information.

New FDA approvals in your inbox

The free 2 Minute Medicine Daily Brief: new approvals, landmark trials and the day's top studies, written by physicians.

Your subscription opens securely in a new tab.

Last updated November 19, 2026 by 2 Minute Medicine.

For healthcare professionals. A summary of public FDA documents and published trials, not medical advice. Check the full prescribing information before prescribing.